February 20, 2026
Co‑manufacturing hemp-derived cannabinoid products and state-regulated cannabis products in the same building is no longer a fringe strategy. It’s a rational response to:
But regulators are also converging on one message: if you run both categories under one roof, you must be able to prove—on demand—that you can prevent cross‑contamination, commingling, diversion, and misbranding.
This guide explains what “co-manufacturing hemp cannabis facility compliance 2025” looks like in practice across the U.S., and how to build a shared GMP backbone that survives inspections.
Informational only, not legal advice.
At the federal level, hemp is defined by the ≤0.3% delta‑9 THC on a dry weight basis threshold, and USDA’s domestic hemp framework is codified at 7 CFR Part 990 (effective since March 22, 2021). See USDA’s hemp laws and regulations overview and the current eCFR text for Part 990:
However, USDA’s authority is primarily production (cultivation). Once you move into foods, dietary supplements, cosmetics, and animal products, other federal regimes matter:
And FDA continues to take the position that many cannabinoid-infused conventional foods/supplements are being marketed unlawfully (often via unapproved drug claims, adulteration, or misbranding). FDA’s enforcement posture is visible in its warning letter hub:
The biggest operational mistake we see is assuming that because hemp is “federally legal,” you can simply add hemp SKUs into a licensed cannabis building (or vice versa). In practice, states tend to require one or more of the following:
Some jurisdictions even publish explicit restrictions. For example, Massachusetts guidance indicates that hemp processing facilities may not be co-located with marijuana operations to ensure compliance with state and federal law:
Takeaway: Before you design a facility, confirm whether your target states allow co-location at all, and under what conditions.
When regulators say “cross-contamination,” they don’t only mean microbial or chemical residue. In a dual-regime plant facility, the most common high-risk scenarios look like this:
In 2025–2026, enforcement pressure is also rising on “look‑alike” products and youth appeal. The FTC and FDA have jointly targeted edible products containing delta‑8 THC that mimic well-known snack brands:
Practical point: Even if your process controls are excellent, weak packaging/label controls can sink the entire compliance posture.
Because this article is U.S.-wide, the right approach is a framework rather than a 50-state list.
Most co-manufacturing facilities end up with at least two regulatory “owners”:
Examples of how different states place hemp cannabinoid oversight:
Some states treat the licensed premises boundary as non-negotiable (one license = one controlled premises). If co-location is allowed, it may require:
If you are building for multi-state expansion, design as if regulators will require dedicated suites—because many will.
Cannabis programs typically require seed-to-sale tracking (e.g., Metrc in many markets). New York’s OCM, for example, published a specific integration deadline for its seed-to-sale rollout for licensees (Dec 17, 2025), with retail inventory entry deadlines in January 2026:
Hemp programs generally do not use seed-to-sale tracking, but regulators increasingly expect batch/lot traceability, COA linkage (often QR), and robust recalls.
Co-manufacturing trap: If your ERP/QMS can’t reconcile cannabis tracked inventory with hemp batch lots and finished goods, you will struggle to prove segregation during an inspection.
The most successful co-manufacturers treat cannabis-only actives as if they were a high-risk allergen family.
At minimum, design for:
If you must share certain equipment (e.g., bottling line), assume you will need validated cleaning plus enhanced line clearance and documentation.
Regulators can tolerate shared walls. They rarely tolerate shared chaos. Implement:
Co-manufacturing works best when you adopt a single QMS backbone and “bolt on” state-specific requirements. Many operators use:
For industry-standardization, ASTM’s D37 committee has published QMS and GMP standards (e.g., D8556 and D8557) designed as practical roadmaps:
Your cleaning program must be more than “wipe it down.” FDA’s food allergen cross-contact guidance emphasizes segregation, dedicated equipment, and verification methods beyond ATP alone. For reference:
Apply the same logic to cannabis-only actives:
Documentation must show: the cleaning method is effective, reproducible, monitored, and verified.
Most cross-contamination events in regulated manufacturing are actually mix-ups.
Implement:
This is where co-manufacturing facilities often fail during surprise inspections: a stray label roll, an open box of pre-printed pouches, or mixed cartons in a staging area.
If you make both categories, your batch record structure should be able to answer:
Best practice: Lock rework to the same regime unless you have a regulator-approved method and labeling pathway.
States often require cannabis goods to be tested via state-licensed labs and panels, while hemp programs may use different lab requirements. California, for example, requires licensed testing labs to maintain ISO/IEC 17025 accreditation:
In hemp programs, some states specify product registration requirements with COA submission (e.g., Utah):
For multi-channel operations:
Even when the same lab is used, sampling rules may differ. Cannabis programs may have distributor-controlled sampling or specific representative sampling rules. Hemp programs may require different batch definitions. Your SOPs should prevent staff from using the “wrong” sampling plan.
A co-manufacturer must be able to show:
Remember that federal agencies have targeted child-appealing edible packaging for delta‑8 THC products (FTC/FDA links above). That enforcement logic is increasingly mirrored by states.
Operational control to implement: a pre-release label approval workflow that includes regulatory mapping, not just brand sign-off.
A robust segregation program uses:
Even if your state doesn’t require formal quarantine, inspectors understand it as a GMP marker of control.
Co-manufacturing multiplies recall complexity. You need to be able to:
FDA’s recall framework is anchored in 21 CFR Part 7 Subpart C, and FDA publishes recall procedure resources:
Best practice: Conduct at least one mock recall per regime per year, plus a combined drill that tests your ability to segregate regimes during a crisis (e.g., “hemp SKU suspected of containing cannabis-only active”).
When you manufacture both categories, your risk profile changes. Many carriers will want to know:
Stock throughput coverage (goods in transit + storage) is commonly discussed in cannabis insurance markets; regardless of provider, ensure your policies reflect dual product families and correct declared operations.
Operational action: update your insurance application narrative to describe segregation controls, validated cleaning, QA release, and recall readiness. Underwriters price uncertainty.
Co-manufacturing is viable in 2025–2026, but only for operators who treat compliance as an engineered system: facility design, segregation, training, cleaning validation, label control, and reconciliation that can withstand both scheduled and unannounced inspections.
If you want help building (or auditing) your co-manufacturing compliance program—SOPs, QMS structure, recall drills, label controls, and state-by-state licensing strategy—use https://www.cannabisregulations.ai/ to get jurisdiction-specific guidance and ongoing compliance support.
